593 related articles for article (PubMed ID: 19770753)
1. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.
Dellinger RP; Tomayko JF; Angus DC; Opal S; Cupo MA; McDermott S; Ducher A; Calandra T; Cohen J;
Crit Care Med; 2009 Nov; 37(11):2929-38. PubMed ID: 19770753
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
Rice TW; Wheeler AP; Bernard GR; Vincent JL; Angus DC; Aikawa N; Demeyer I; Sainati S; Amlot N; Cao C; Ii M; Matsuda H; Mouri K; Cohen J
Crit Care Med; 2010 Aug; 38(8):1685-94. PubMed ID: 20562702
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
Opal S; Laterre PF; Abraham E; Francois B; Wittebole X; Lowry S; Dhainaut JF; Warren B; Dugernier T; Lopez A; Sanchez M; Demeyer I; Jauregui L; Lorente JA; McGee W; Reinhart K; Kljucar S; Souza S; Pribble J;
Crit Care Med; 2004 Feb; 32(2):332-41. PubMed ID: 14758145
[TBL] [Abstract][Full Text] [Related]
4. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis.
Albertson TE; Panacek EA; MacArthur RD; Johnson SB; Benjamin E; Matuschak GM; Zaloga G; Maki D; Silverstein J; Tobias JK; Haenftling K; Black G; Cowens JW;
Crit Care Med; 2003 Feb; 31(2):419-27. PubMed ID: 12576946
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis.
Root RK; Lodato RF; Patrick W; Cade JF; Fotheringham N; Milwee S; Vincent JL; Torres A; Rello J; Nelson S;
Crit Care Med; 2003 Feb; 31(2):367-73. PubMed ID: 12576938
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
[TBL] [Abstract][Full Text] [Related]
7. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial.
Eid A; Wiedermann CJ; Kinasewitz GT
Anesth Analg; 2008 Nov; 107(5):1633-8. PubMed ID: 18931224
[TBL] [Abstract][Full Text] [Related]
8. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
[TBL] [Abstract][Full Text] [Related]
9. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
Bakker J; Grover R; McLuckie A; Holzapfel L; Andersson J; Lodato R; Watson D; Grossman S; Donaldson J; Takala J;
Crit Care Med; 2004 Jan; 32(1):1-12. PubMed ID: 14707554
[TBL] [Abstract][Full Text] [Related]
10. Nitrogen sparing effect of structured triglycerides containing both medium-and long-chain fatty acids in critically ill patients; a double blind randomized controlled trial.
Lindgren BF; Ruokonen E; Magnusson-Borg K; Takala J
Clin Nutr; 2001 Feb; 20(1):43-8. PubMed ID: 11161543
[TBL] [Abstract][Full Text] [Related]
11. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study).
Jaimes F; De La Rosa G; Morales C; Fortich F; Arango C; Aguirre D; Muñoz A
Crit Care Med; 2009 Apr; 37(4):1185-96. PubMed ID: 19242322
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of an endotoxin-binding phospholipid emulsion.
Gordon BR; Parker TS; Levine DM; Saal SD; Hudgins LC; Sloan BJ; Chu C; Stenzel KH; Rubin AL
Ann Pharmacother; 2003; 37(7-8):943-50. PubMed ID: 12841798
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of phospholipid liposomes in the treatment of neuropsychological disorders associated with the menopause: a double-blind, randomised, placebo-controlled study.
Rachev E; Nalbansky B; Kolarov G; Agrosì M
Curr Med Res Opin; 2001; 17(2):105-10. PubMed ID: 11759177
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a complex homeopathic medication (Sinfrontal) in patients with acute maxillary sinusitis: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial.
Zabolotnyi DI; Kneis KC; Richardson A; Rettenberger R; Heger M; Kaszkin-Bettag M; Heger PW
Explore (NY); 2007; 3(2):98-109. PubMed ID: 17362845
[TBL] [Abstract][Full Text] [Related]
15. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
16. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients.
Heemskerk S; Masereeuw R; Moesker O; Bouw MP; van der Hoeven JG; Peters WH; Russel FG; Pickkers P;
Crit Care Med; 2009 Feb; 37(2):417-23, e1. PubMed ID: 19114895
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
[TBL] [Abstract][Full Text] [Related]
18. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.
Dhainaut JF; Tenaillon A; Hemmer M; Damas P; Le Tulzo Y; Radermacher P; Schaller MD; Sollet JP; Wolff M; Holzapfel L; Zeni F; Vedrinne JM; de Vathaire F; Gourlay ML; Guinot P; Mira JP
Crit Care Med; 1998 Dec; 26(12):1963-71. PubMed ID: 9875905
[TBL] [Abstract][Full Text] [Related]
19. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
[TBL] [Abstract][Full Text] [Related]
20. Neutralization of endotoxin by a phospholipid emulsion in healthy volunteers.
Gordon BR; Parker TS; Levine DM; Feuerbach F; Saal SD; Sloan BJ; Chu C; Stenzel KH; Parrillo JE; Rubin AL
J Infect Dis; 2005 May; 191(9):1515-22. PubMed ID: 15809911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
